Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes

Impact · against what's priced in

Vaxcyte is raising $1 billion through equity and convertible notes to secure its runway for the VAX-31 launch. While the capital infusion eliminates immediate funding risk for clinical trials and manufacturing, it introduces significant equity dilution and new debt obligations.

PCVX−0.10

No priced-in read yet